Terminated NA INTERVENTIONAL 2-arm NCT01033357

Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

A Long Term Safety Study of the Vascular Wrap(TM) Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® Graft in the Upper Extremity for Hemodialysis Vascular Access

Sponsor: Angiotech Pharmaceuticals

Conditions End Stage Renal Failure on Dialysis Hyperplasia

Interventions Graft, Vascular Wrap Lifespan® ePTFE Vascular Graft Only

Updated 8 times since 2017 Last updated: Feb 7, 2013 Started: Mar 31, 2008 Primary completion: Mar 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Imbalance in the # graft infections between the tx's (graft vs. graft + wrap)

Other terminated trials from Angiotech Pharmaceuticals

ESRD · Phase NA · Apr 2009

More terminations from Angiotech Pharmaceuticals

Other End Stage Renal Failure on Dialysis trials with similar outcome

Browse all End Stage Renal Failure on Dialysis trials

A NA clinical study on End Stage Renal Failure on Dialysis and Hyperplasia, this trial is terminated or withdrawn. The trial is conducted by Angiotech Pharmaceuticals and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated NA
Sep 2024 — Sep 2025 [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Apr 2022 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Apr 2022 [monthly]

Terminated NA

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated NA
Feb 2017 — Jun 2018 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angiotech Pharmaceuticals

Data source: Angiotech Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cincinnati, United States , Flint, United States , Flushing, United States , Fort Worth, United States , Fresno, United States , Gainsville, United States , Hagerstown, United States , Indianapolis, United States , Inglewood, United States , Jacksonville, United States and 18 more locations